Fandom

Scratchpad

Groups by Maintenance Drugs

216,203pages on
this wiki
Add New Page
Discuss this page0 Share

Ad blocker interference detected!


Wikia is a free-to-use site that makes money from advertising. We have a modified experience for viewers using ad blockers

Wikia is not accessible if you’ve made further modifications. Remove the custom ad blocker rule(s) and the page will load as expected.

Maintenance Drugs

1. VP-16

2. Vioxx

3. Gleevec

  • TinysunflSchaut, Nikki - tumor started growing, stopped drug

4. Celebrex

5. Irinotecan and Temodar

6. Sutent

Alternative and Complementary

TinysunflBraswell, Christian

TinysunflOrantes, Meliza

Clinical Studies

http://www3.interscience.wiley.com/cgi-bin/abstract/112151892/ABSTRACT?CRETRY=1&SRETRY=0

Response to vinorelbine and low-dose cyclophosphamide chemotherapy in two patients with desmoplastic small round cell tumor Andrea Ferrari, MD 1 *, Federica Grosso, MD 2, Silvia Stacchiotti, MD 2, Cristina Meazza, MD 1, Elena Zaffignani, MD 1, Alfonso Marchianò, MD 3, Michela Casanova, MD 1 1Pediatric Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy 2Adult Sarcoma Medical Oncology Unit, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy 3Radiology Department, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy

email: Andrea Ferrari (andrea.ferrari@istitutotumori.mi.it)

  • Correspondence to Andrea Ferrari, Pediatric Oncology Unit, Istituto Nazionale Tumori, Via G. Venezian, 1-20133 Milano MI, Italy.

Keywords desmoplastic small round cell tumor • low-dose cyclophosphamide • metronomic therapy • vinorelbine


Abstract We report two cases of abdominal desmoplastic small round cell tumor (DSRCT) that showed a clinical response to the vinorelbine/low-dose cyclophosphamide combination that has been claimed to be effective for rhabdomyosarcoma. This observation may prompt further investigation into the activity of such a regimen in DSRCT patients with recurrent or refractory disease, with a view to a possible future role as maintenance therapy in controlling minimal residual disease in patients who achieve complete remission with intensive induction multimodality therapy. Pediatr Blood Cancer © 2005 Wiley-Liss, Inc.

DSRCT References

[BACK]

Also on Fandom

Random wikia